Your browser does not support inline frames or is not configured to display inline frames. The first commercial use InterVapor absorption Medications
system for endoscopic lung volume reduction in patients with severe emphysema >> << have been made in Germany last November. The patient was successfully treated with InterVapor, >> << endoscopic lung volume reduction system for the treatment of severe emphysema >> << that uses bodyBЂ ™ natural healing process, leaving no foreign material
in the lungs. The patient was treated
Team Thoraxklinik in Heidelberg, Germany, led by
Prof. Dr. Felix Herth and is recognized as a leading institution
on the latest therapeutic options for people with emphysema. BЂњAs investigators in court a couple, we saw the benefits most common side effects of lasix
our patients received InterVapor, and we are pleased to enter
Selected InterVapor, BЂ "commented Prof. Dr. Felix
Herth, Chief, Department of Pulmonology, Thoraxklinik
Heidelberg. BЂњIt especially fitting that the first patient case
in November, which marks the COPD Awareness Month, as
InterVapor offers a new treatment option for patients who
looking for help from emphysema. BЂ "
Medical Acquisitions announced on 9 January this year, it closed
series C funding cycle. Round-headed Singapore
Group Point Crescent, existing investors, Maverick Capital,
Ventures beginning, GBS Venture Partners, WRF Capital, arboretum
Ventures and Affinity Capital, making additional investments. Sami
Cindy, crescent point, Managing Partner, will enter the acquisition of medical
Board of Directors. Moelis Company acted as financial advisor
Company in connection with the financing. The company has received CE mark approval to InterVapor in September
and recently announced the TGA approval InterVapor on the market
Australia. R. King Nelson, President and CEO of Acquisitions
Medical commented BЂњFinalizing a very successful round of financing
is another positive step for the absorption of Medical. We
pleased with the addition of Crescent Point to our board and we
equally pleased that our current investors are still committed
absorption of medical, as we continue to commercialize InterVapor. BЂ "
About emphysema / COPD Emphysema is a progressive disease in which lung
damaged. This leads to a condition called
hyperinflation, which affects the respiratory function and makes patients
make short, shallow breaths, greatly affects quality of life. InterVapor system directly causes the reduction of hyperinflation
problem for patients with severe emphysema. This non-surgical
procedure that applies to the hyperinflated lung units with heating
water vapor, and starts a natural healing process bodyBЂ ™ s,
gradually reducing considered part of the lungs and increase the ability to breathe
more fully. Unlike other approaches to reduce lung volume, InterVapor does not leave
foreign matter in the lungs, which may require additional procedures
to set up or removal. The results obtained in court
PAIR demonstrated clinically significant improvement in lung function
and quality of life for patients with severe emphysema. Global incidence of chronic obstructive pulmonary disease
(COPD), which includes emphysema, is on the rise, and will >> << third leading cause of death in 2030. In the U.S., where nearly 5
million people are diagnosed with emphysema, she already holds this position
with one person dying every 4 minutes from COPD. Exhausting and expensive, almost $ 50 billion was spent solution >> << direct and indirect costs of COPD in the U.S. in 2010. .
